Bacteria News and Research

RSS

Clinical data emphasizing on efficacy and potency of torezolid to be presented

Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA.

14 Sep 2009

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

14 Sep 2009

Scarab Genomics and Neoclone sign license agreement

Scarab Genomics, a leader in E coli technology, has entered into a license agreement with NeoClone to market and distribute their proprietary antibodies against Shiga toxin.

11 Sep 2009

Positive results from Mpex' Phase 2b clinical trial with Aeroquin

Mpex Pharmaceuticals, Inc. today announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Trial results showed that nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa (P. aeruginosa) in sputum after 28 days of dosing versus placebo.

11 Sep 2009

Children's Hospital to determine optimal duration of antimicrobial treatment for UTIs

In the largest study of its kind, pediatric researchers at The Children's Hospital of Philadelphia have received a federal contract for a project to determine the most beneficial method of using antibiotics to treat urinary tract infections (UTIs) in children.

11 Sep 2009

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

New treatment strategies for multiple sclerosis

The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.

10 Sep 2009

Miracles of the immune system discussed at the 2nd European Congress of Immunology

"I think it will not surprise you if I say that the immune system is one of our most important organ systems. Its relevance is obvious if only for the fact that it has been reinvented several times throughout the evolution of life," says Professor Andreas Radbruch, President of the German Society of Immunology and Director of the Deutsches Rheuma-Forschungszentrum, Berlin. He lectured about the miracle of our immune system at the Opening Press Conference of the 2nd European Congress of Immunology.

10 Sep 2009

Hanson Technologies receives patent for its UltraRapid technology

Hanson Technologies, Inc., an innovator in rapid biosensing solutions for food pathogen screening, today announced the issuance of a U.S. Patent entitled Agricultural Screening System and Method for Detection of Infectious Microorganisms. The U.S. patent describes the Company's method for screening for the presence of pathogenic microorganisms in vegetables, fruits, nuts and other plant material intended for human and animal consumption.

10 Sep 2009

Federal contract awarded to Children's Hospital of Philadelphia to study use of antibiotics in children

10 Sep 2009

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health (“NIH”) has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.

9 Sep 2009

Bioluminescence imaging demystifies causes of infectious diseases

By attaching light-emitting genes to infectious bacteria in an experimental system, researchers at University College, Cork, Ireland, have been able to track where in the body the bacteria go - giving an insight into the path of the infection process leading to the development of more targeted treatments.

9 Sep 2009

URV’s biosensor can detect typhoid causing bacteria instantly

A research group from the Rovira i Virgili University (URV) in Tarragona has developed a biosensor that can immediately detect very low levels of Salmonella typhi, the bacteria that causes typhoid fever. The technique uses carbon nanotubes and synthetic DNA fragments that activate an electric signal when they link up with the pathogen.

9 Sep 2009

New technique for tumor therapy under study

In the scientific journal PLoS ONE, Sara Bartels and Siegfried Weiss of the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany now show how the bacteria migrate into tumours. A messenger substance from the immune system is the door opener: It makes blood vessels in the cancerous tissue permeable; enabling the bacteria to conquer and destroy the tumour.

9 Sep 2009

Phenotype microarrays compare growth characteristics of pathogenic and non-pathogenic E. coli

Dr Karin Heurlier and colleagues at the Universities of Nottingham and Birmingham in conjunction with Biolog Inc of California USA, used powerful high throughput analytical tools (phenotype microarrays) that enabled them to compare about 2000 growth characteristics of several pathogenic (disease-causing) E. coli with a non-pathogenic laboratory E. coli strain.

9 Sep 2009

Inactivation of ClpX gene may help treat anthrax poisoning

Scientists from the University of California (San Diego) have identified a gene in B. anthracis that not only contributes to the severity of the anthrax disease but also makes it more difficult for a patient's immune system to fight the infection.

8 Sep 2009

New iso-active foaming gel delivers active ingredients to hard-to-reach areas of the mouth

The makers of Aquafresh(R) and Sensodyne(R) introduce a breakthrough technology in toothpaste - new iso-active(R) Foaming Gel. Iso-active has a revolutionary delivery system that disperses active ingredients quickly, penetrating those hard-to-reach areas of the mouth.

8 Sep 2009

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.

8 Sep 2009

BioTrove partners with FDA to investigate the utility of SNAP system

BioTrove announced a collaboration with the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research to investigate the utility of the company’s Standardized NanoArray PCR (SNAP) gene expression profiling system for the rapid and specific detection of pathogens in the nation’s blood supply.

8 Sep 2009

New probiotic provides protection against the fatal E. coli disease

Researchers in Australia are developing diversionary tactics to fool disease-causing bacteria in the gut. Many bacteria, including those responsible for major gut infections, such as cholera, produce toxins that damage human tissues when they bind to complex sugar receptors displayed on the surface of cells in the host's intestine.

8 Sep 2009

Bacteria News and Research

Clinical data emphasizing on efficacy and potency of torezolid to be presented

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Scarab Genomics and Neoclone sign license agreement

Positive results from Mpex' Phase 2b clinical trial with Aeroquin

Children's Hospital to determine optimal duration of antimicrobial treatment for UTIs

NovaBay begins clinical studies for treating impetigo skin infection

New treatment strategies for multiple sclerosis

Miracles of the immune system discussed at the 2nd European Congress of Immunology

Hanson Technologies receives patent for its UltraRapid technology

Federal contract awarded to Children's Hospital of Philadelphia to study use of antibiotics in children

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Bioluminescence imaging demystifies causes of infectious diseases

URV’s biosensor can detect typhoid causing bacteria instantly

New technique for tumor therapy under study

Phenotype microarrays compare growth characteristics of pathogenic and non-pathogenic E. coli

Inactivation of ClpX gene may help treat anthrax poisoning

New iso-active foaming gel delivers active ingredients to hard-to-reach areas of the mouth

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

BioTrove partners with FDA to investigate the utility of SNAP system

New probiotic provides protection against the fatal E. coli disease

Microbiology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo